Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:
Ying Han

Description

Summary

This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Official Title

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Keywords

Glaucoma, Open-Angle Ocular Hypertension Hypertension Glaucoma Timolol Bimatoprost Bimatoprost sustained-release Sham Bimatoprost SR Dose A Bimatoprost SR Dose B

Eligibility

You can join if…

Open to people ages 18 years and up

  • Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.

You CAN'T join if...

  • Previous enrollment in another Allergan Bimatoprost SR Study
  • Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye
  • Anticipated need for laser eye surgery within the first 52 weeks of the study duration
  • History of glaucoma surgery

Locations

  • University of California San Francisco accepting new patients
    San Francisco California 94143 United States
  • North Bay Eye Associates, Inc., accepting new patients
    Petaluma California 94954 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Allergan
Links
More Information
ID
NCT02250651
Phase
Phase 3
Lead Scientist
Ying Han
Study Type
Interventional
Last Updated
February 7, 2018